Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Articles, guides, and regulatory updates from our community.
A 2026 study in 3 Biotech fabricated a BPC-157 chitosan hydrogel with promising antibacterial and drug-delivery properties. Here's what the research suggests.
By Peptide Association Research Team
New research explores how antimicrobial peptide-functionalized nanoparticles activated by near-infrared light may help eradicate biofilms in diabetic wounds.
By Peptide Association Research Team
New research shows continuous spin-freeze-drying of PEGylated peptides can scale to GMP manufacturing while maintaining product quality and stability.
By Peptide Association Research Team
New research explores continuous spin-freeze-drying scale-out for PEGylated peptides, showing consistent quality from lab to GMP production. Learn what this means.
By Peptide Association Research Team
A 2026 study found BPC-157 and hybrid analogs may inhibit acetylcholinesterase, a key enzyme in Alzheimer's disease. Learn what the research means.
By Peptide Association Research Team
A 2026 review in Pharmaceutics examines BPC-157's development barriers, formulation challenges, and why human clinical data remains critically limited.
By Peptide Association Research Team
A 2026 review in Pharmaceutics examines BPC-157's biopharmaceutical challenges, pharmacokinetic gaps, and the barriers standing between preclinical promise and human trials.
By Peptide Association Research Team
A 2026 review in Pharmaceutics examines why BPC-157 lacks approved formulations, validated dosing, and completed Phase II trials despite 30+ years of preclinical data.
By Peptide Association Research Team
New research explores how mitochondria-targeted peptide nanoparticles may protect the liver from ischemia-reperfusion injury. Learn what the science shows.
By Peptide Association Research Team